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Abstract 
Introduction: Fibroblast activation protein-α (FAP-α) belongs to the family of prolyl-specific 
serine proteases. FAP-α displays both exopeptidase and endopeptidase/gelatinase/collagenase 
activityies. FAP-α protein and/or activity have been associated with fibrosis, inflammation and 
cancer, but the protein is undetectable in most normal tissues. FAP-α is selectively expressed at 
sites of tissue remodeling and repair and enhances tumor progression, suggesting that this protease 
may be a therapeutic target to treat human disorders associated with fibrotic dysregulation. 
Areas covered: In this review, we summarize the mechanisms driving tissue fibrosis and describe 
some of the enzymes involved in fibrosis, concentrating on FAP-α. We describe its enzymatic 
properties, discuss the tools developed to control its activity and the problem of selectivity toward 
the other proteases of the family and outline its potential biological substrates. We also consider 
non-enzymatic functions of this protein and suggest that repression of FAP-α expression may 
represent therapeutic options. 
Expert opinion: Questions remain regarding the biological functions of FAP-α, either dependent or 
independent of its enzyme activity. However, as progress is underway to develop FAP-α-specific 
inhibitors and therapeutic antibodies, its role in diseases associated with fibrosis is starting to 
emerge, ultimately leading to novel therapeutic options for inflammatory and oncologic diseases. 
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1. Prolyl-specific proteases and FAP-α in fibrogenic disorders 
1.1. Fibrosis, fibroblasts and myofibroblasts. 
Fibrosis is a non-specific terminal pathway following local inflammation and scaring. It is the 
hallmark of many chronic inflammatory diseases and cancer as well as a predictor of dysfunction of 
solid organ transplants and implanted biomaterials [1,2]. The pathogenesis of fibrosis involves an 
initial and repetitive tissue injury leading to abnormal tissue repair involving inflammatory and 
mesenchymal cells, thickening of the surrounding tissue and functional impairment. In response to 
tissue injury, the repair process may result in two distinct phenomena, a normal regenerative 
process, limited in time, in which injured cells are replaced by cells of the same type. In chronic 
pathological fibrotic responses, connective tissue, including myofibroblasts, replaces normal tissue 
with an uncontrolled deposition of extracellular matrix (ECM). This pathological fibrotic process 
finally results in the replacement of normal tissue with permanent scar tissue [3]. The mechanisms 
of fibrosis development depend on the underlying disease or local tissue properties and an 
inflammatory response to an initial injury, whatever the injury, as well as recruitment of 
macrophages. These cells can synthesize locally a variety of growth factors, pro-inflammatory 
cytokines, enzymes and ECM proteins that influence fibrogenesis. However, the mechanisms that 
drive fibrogenesis are different from the mechanisms inducing inflammation. Transforming growth 
factor-beta (TGFβ), predominantly produced by circulating monocytes and tissue macrophages as 
well as cancer cells, has been the most intensively studied pro-fibrogenic factor [4,5].  
Myofibroblasts are fibroblast-derived cells that are present at very low frequency in normal tissues, 
but are activated by a variety of stimuli [5,6] (Figure 1) and their number increases in healing 
wounds and in fibrogenic disorders. Fibrosis-associated proliferating activated (myo)fibroblasts 
express specific molecules induced by the activation process when compared with their resting 
counterparts. They secrete large amounts of ECM proteins, in particular type I and type II collagens. 
The main feature of myofibroblasts is represented by an important contractile apparatus expressing 
α-smooth muscle actin (α-SMA) and promoting cell migration. Thus, activation of resident tissue 
fibroblasts is a key event of fibrosis development and/or progression, resulting from inappropriate 
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properties of these cells in response to tissue stress. The increased number of (myo)fibroblasts 
associated with fibrosis could originate from resident proliferating tissue fibroblasts, from 
circulating bone-marrow-derived fibrocytes, or be the consequence of epithelial to mesenchymal 
(EMT) or endothelial to mesenchymal (EndMT) cell trans-differentiation mechanisms.  
In oncogenic diseases, cancer-associated fibroblasts (CAF) are recruited to the stroma of tumors and 
influence a variety of oncogenic processes by secreting growth factors and proteases, and producing 
an altered ECM [7]. In chronic inflammatory disorders, activated myofibroblasts accumulate at sites 
of injury and deposit excessive ECM proteins associated with impaired degradation by 
macrophages [8]. In cell/tissue transplantation or tissue engineering the biological response at the 
interface between host tissue and transplanted/implanted bio-materials can trigger a variety of 
adverse tissue responses such as local inflammation and fibrosis, hindering long-term functionning 
of the grafts or devices.  
 
Figure 1. Myofibroblast formation. 
 
Proteolytic degradation of the ECM is necessary for tissue remodeling, repair and invasion, and 
ultimately in the process of fibrosis. During the normal process of tissue remodelling, the final 
stages include reduced synthesis and increased proteolytic degradation of collagens, regeneration of 
the normal tissue cells and the vascular network, and disappearance of myofibroblasts by apoptosis. 
Any disruption of the proteolytic balance in pathological processes may compromise tissue 
homeostasis. Specific proteases are involved in the development, maintenance and regression of 
tissue fibrosis. In this review, we will concentrate on the potential role of fibroblast activation 
protein-α (FAP-α) in fibrogenic processes in inflammation and cancer. 
 
1.2. Prolyl-specific peptidases in fibrogenic diseases. 
As production of proline-rich ECM proteins and collagens by activated (myo)fibroblasts is a key 
event in the development of fibrosis, it can be hypothesized that prolyl-specific proteases are 
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involved in tissue fibrosis by aberrantly processing tissue-derived biologically active prolyl-
containing peptides in response to tissue injury, inflammation or cancer. The prolyl residue, either 
in terminal position or in the core of peptides, imposes conformational constraints of the amino acid 
chain. Of the known human proteases, only a few prolyl-specific proteases, including the non-post-
prolyl-cleaving matrix metalloproteases (MMPs) and the post-prolyl-cleaving proteases related to 
dipeptityl amino-peptidase IV (DPP IV) have been described [9-16], suggesting that the amino acid 
selectivity of prolyl-specific proteases for proline are implicated in fibrogenic processes. 
Alternatively, non-enzymatic functions of these proteins may also be involved (see below). The role 
of MMPs in fibrogenic diseases has been previously reviewed by several authors [for example, 17], 
to whom the readers are referred since we will not repeat here this information. We will concentrate 
on the prolyl-peptidases of the DPP IV family, in particular the potential interest of targeting FAP-α 
in fibrosis-associated disorders [16]. 
 
2. The family of proline-specific peptidases (the DASH-family). 
The post-prolyl-cleaving-specific peptidases encompasses several proteins: dipeptidyl peptidase 
(DPP) IV, quiescent cell proline dipeptidase (QPP/DPPII/DPP7), fibroblast activation protein-α 
(FAP-α), prolyl oligopeptidase (POP), DPP8 and DPP9, and the inactive DPP6 and DPP10. They 
include exopeptidases, such as DPP IV, FAP-α, QPP, DPP8 and DPP9, or endopeptidases such as 
POP, DPP8 and FAP-α. DPP IV and FAP-α are membrane-bound, while POP, DPP8 and DPP9 are 
cytoplasmic. These serine proteases exhibit similarities in their catalytic behavior [18]. The Gly-
Trp-Ser-Tyr-Gly sequence around the active Ser, and the organisation of the catalytic triad are 
conserved between the members of the family [9-15,18]. DPP IV and FAP-α share the highest 
sequence homology. The exopeptidase enzymatic activity of FAP-α is comparable to that of DPP 
IV, but in addition FAP-α also displays endoproteolytic activity comparable to POP and 
gelatinase/collagenase activity (Figure 2). Ubiquitously-expressed enzymes in various cellular 
locations and with comparable overlapping enzymatic activities question the exact site, mode of 
action, and biological functions of these proteins in cells and tissues. 
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Figure 2. Prolyl-specific peptidases: exoproteolytic (left) and endoproteolytic (right) enzymatic 
activities, with the preferred amino acid sequences when known 
 
We will first rapidly review the members of the family of serine prolyl-specific proteases other than 
FAP-α, then focus in more detail on FAP-α. 
 
2.1. Post prolyl-cleaving peptidases other than FAP-α. 
DPP IV/CD26 (EC 3.4.14.5.) is the representative member of the family. DPP IV is a homodimeric 
type II integral membrane glycoprotein able to release X-Pro or X-Ala dipeptides from free N-
terminal sequences, allowing selectivity over prolyl-endopeptidases, whereas any amino acid is 
permitted at the X position of the substrate, branched amino acids being preferred. Each subunit 
comprises a C-terminal α/β hydrolase domain and an N-terminal eight-bladed β-propeller domain 
forming a large cavity containing the active site [19,20]. Potential substrates of DPP IV include 
cytokines, chemokines and growth factors carrying an N-terminal X-Pro- or X-Ala-motif, resulting 
in activation, modulation of function or initiation of degradation of the peptides. Inhibitors of DPP 
IV activity, the gliptin family of therapeutics, are in clinical use for type 2 diabetes [21]. The 3D 
structure (X-ray crystal structure) and kinetic characteristics of DPP IV have been determined 
[19,20,22-25]. DPP IV, known as CD26, is a marker of T-cell activation in immune and 
inflammatory diseases [26]. DPP IV activity has been linked to prostate, colon and lung carcinoma 
or glioblastoma tumor cells [27-30]. DPP IV expression, as a receptor for tumor-associated 
fibronectin on endothelial cells favors tumor cell adhesion and metastasis, independently of its 
enzymatic activity [31].  
POP (PEP/PREP; EC 3.4.21.26.) is a very conserved and widely distributed post-prolyl-
endopeptidase hydrolyzing peptides under 30 residues long at the carboxylic side of proline 
residues in the core of the chain [12-14,32,33]. POP is able to form protein-protein interactions with 
other cellular proteins [9,34]. The 3D structure, flexibility, substrate docking and kinetic 
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characteristics of POP from mamalian and non-mammalian origin have been determined [35-38]. 
POP shows a cylindrical structure consisting of an α/β-hydrolase domain containing the catalytic 
triad Ser554, Asp641, His680 as an internal cavity between the two catalytic domains and an unusual 
seven-bladed β-propeller non-catalytic domain. Synthetic inhibitors based on Z-prolyl-prolinal 
(ZPP) have been developed [32,37].  
QPP (DPPII/DPP 7; EC 3.4.14.2) is a homodimeric glycoprotein with protease characteristics 
identical to DPP IV, but with no sequence homology, active at acidic pH and located in intracellular 
post-Golgi vesicles distinct of lysosomes. QPP is involved in protein maturation and catabolism, 
and in immunological disorders [39-41].  
DPP8 and DPP9 (EC EC 3.4.14.) are very similar and ubiquitously expressed, soluble cytosolic 
enzymes of ~ 100 kDa with DPP IV-like activity but without a transmembrane domain [42-47] and 
exopeptidase activity. DPP8 has the same stucture as DPP IV, an N-terminal propeller domain, and 
a C-terminal peptidase domain. DPP8/9 inhibition can attenuate macrophage activation.  
DPP6 and DPP10 are less deeply characterized. These proteins have no detectable protease 
activity, due to the absence of the conserved serine residue present in the catalytic domain of serine 
proteases. DPP6 and DPP10 regulate the expression and gating characteristics of membrane 
potassium channel complexes [48,49].  
The role in fibrogenic disorders of DPP8, DPP9, DPP6 and DPP10, is presently not known in detail 
and will not be discussed in this review. 
 
3. Fibroblast activation protein-alpha (FAP-α). 
3.1. The biology and enzymology of FAP-α. 
FAP-α (seprase; EC 3.4.21.B28) is an homodimeric type II integral membrane prolyl-specific serine 
protease belonging to the clan SC proteases and the S9B prolyl oligopeptidase subfamily [50-53].  
FAP-α is most closely related to DPP IV, displaying an overall 50% similarity in sequence and a 
70% similarity in the catalytic region. FAP-α exhibits a DPP IV-like fold and has a molecular 
weight and an enzymatic activity comparable to DPP IV, removing X-Pro-dipeptides from the free 
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N-terminus of peptides (exopeptidase activity); but in addition, FAP-α also displays endoprotease 
activity like POP, and gelatinase/collagenase activities (endopeptidase activity) like MMPs [16,54-
58]. However, N-terminus-free substrates are cleaved by FAP-α with a 100-fold lower catalytic 
efficiency compared to DPP IV [59]. FAP-α activity is inhibited by general serine-protease 
inhibitors and boronic acid peptides [60-62]. There are at least 11 known alternative splice variants 
of the most frequent FAP-α primary transcript, some of them encoding isoforms devoid of 
enzymatic activity (the ACE-View Database, cited in [63]). FAP-α in humans is encoded by the 
FAP-α gene, located at 2q23 on chromosome 2 [64]. DPP IV and FAP-α genes are localized close 
to each other on chromosome 2 and they are thought to result from gene duplication. Co-expression 
of both enzymes is frequently observed and FAP-α can associate with DPP IV as heteromeric 
complexes possessing both prolyl exopeptidase and prolyl endopeptidase activities [52,55,65,66], 
suggesting that both molecules can reciprocally regulate each other.  
FAP-α features an α/β hydrolase domain (characterized by the catalytic site sequence Gly-X-Ser-X-
Gly) and an eight-bladed β-propeller domain. FAP-α is biosynthesized as an inactive 97 kDa 
subunit (760 amino acids, GenBank accession number U76833, 97 kDa) which needs dimerization 
(170 kDa) to become active. Several mutagenesis experiments have provided information about the 
functions of defined amino acids for either the hydrolytic or the adhesive properties of FAP-α 
(Table 1). The results demonstrated that its exo- and endo-peptidase activities and the adhesive and 
migratory properties could be differentiated. 
 
Table 1. Mutagenesis experiments performed on FAP-α. 
 
FAP-α aminoacid sequence predicts a 6-amino acid cytoplasmic tail, a 20-amino acid 
transmembrane domain and a 734-amino acid extracellular domain [50,52,53] containing the 
catalytic Ser624, Asp702 and His734 charge relay triad located at the carboxyl terminus of each subunit 
(Figure 3A).  
 
9 
 
Figure 3. Structure of the FAP-α protein. 
 
The structures of the active sites of FAP-α, POP and DPP IV are very similar [19,20,59,67,69-71], 
suggesting comparable enzymatic mechanisms, conformational changes and ligand binding. The 
crystal structure of the FAP-α homodimer (PBD ID:1Z68) shows that each monomer consists of an 
α/β-hydrolase domain (aa27-53 and aa493-760), and an eight blade-β-propeller domain (aa54-492) 
enclosing a large cavity. Both the hydrolase and propeller domains participate in the FAP-α 
dimerization. Two ways are available for the substrates to reach FAP-α active site: through the 
cavity formed between the α/β hydrolase domain and the β-propeller domain, or through a central 
hole formed by the blades in the β-propeller (Figure 3B). FAP-α has a short 6-amino acid 
cytoplasmic domain, suggesting that by itself the cytoplasmic domain is probably not able to 
transmit signals. The active catalytic triad, Ser624, Asp702 and His734, is located in a small pocket of 
the large cavity at the interface of the α/β-hydrolase and the β-propeller domains. The proline 
residue of substrates is accommodated in a hydrophobic pocket composed by Tyr625, Val650, Trp653, 
Tyr656, Trp660 and Val705, whereas the N-terminal end of substrate peptides is recognized by two 
glutamates (Glu203-Glu204) contained in an α-helix of the β-propeller domain, necessary to the 
exopeptidase activity; unlike the negatively charged Asp663 in DPP IV active site, FAP-α has a 
neutral Ala657 residue at the corresponding position, explaining its dual exo/endopeptidase activities 
[7,59,61,62,67]. Thus, differences in the vicinity of the Glu203-Glu204 motif and the reduced acidity 
of the active site due to the presence of Ala657 determine the dual substrate preference of FAP-α 
[59,67]. A polymorphism encoding Ser363 to Leu in the sixth blade of the β propeller domain in 
FAP-α alters its tertiary structure and ablates dimerization and enzymatic activity. The mutated 
protein is detectable only in the endoplasmic reticulum (ER) and not at the cell surface. In the ER, 
Ser363Leu FAP-α upregulates the chaperone BiP/GRP78, the stress response ATF6 and phospho-
elF2A and was degraded by the proteasome [72], pointing to the importance of FAP-α 
conformation. The in vitro kinetics values (KM) of hydrolysis of peptide substrates have been 
determined for the exopeptidase (dipeptidylpeptidase) and endopeptidase (prolyl endopeptidase) 
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activities of FAP-α, respectively (Table 2).  
 
Table 2. Kinetics constants of FAP-α on small peptides. 
 
FAP-α protein and/or activity has been associated with several human diseases. FAP-α protein is 
generally undetectable in most normal tissues whereas it is selectively expressed at sites of tissue 
remodeling and repair: dermal fibroblasts of fetal skin during development, granulation tissues of 
healing wounds, inflamed synovial tissues, activated hepatic stellate cells and myofibroblasts from 
cirrhotic liver,  subpopulations of reactive cancer-associated stromal fibroblasts (CAFs) in epithelial 
cancers and some cancer cells, such as glioblastomas and glioma cells, malignant cells of bone and 
soft tissue sarcomas and melanomas, or some carcinomas,. Enzymatically inactive intracellular 
alternative splice variants of FAP-α may also be expressed under some circumstances 
[16,30,52,68,72-77]. FAP-α enhances tumor progression by increasing angiogenesis and ECM 
degradation, and by reducing the antitumor response of the immune system mediated by the 
STAT3-CCL2 axis [75,78,79]. 
 
3.2. FAP-α substrates and targets.  
Defining the exact substrates of FAP-α is a very challenging task since potential substrates of FAP-
α include small peptides and larger proteins, involving either the exopeptidase or the endopeptidase 
activities of the enzyme. Consequently, very few endogenous substrates of FAP-α have been 
formally identified. Moreover, substrate selectivity toward the other members of the DASH family 
is an issue; however, some sequences can differentiate the proteases of the family. In small peptides 
and proteins, FAP-α endopeptidase activity displays a clear, but not exclusive, preference for -Gly-
Pro- sequences [80]. Many cytokines and chemokines associated with inflammation and bearing X-
Pro- N-terminal sequences, neuropeptide Y (NPY), peptide YY (PYY), substance P and brain-type 
natriuretic peptide have been shown to be potential substrates of the dipeptidase activity of FAP-α, 
but only in vitro [81]. Some proteins have been demonstrated to be FAP-α substrates: FAP-α 
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exhibits post-proline cleaving endopeptidase activity for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus 
sequences, on substrates which include regulators of proteolytic or cell growth pathways such as α2-
antiplasmin, serpins, (the proteolysis of α2-antiplasmin by FAP-α increasing its plasmin inhibitory 
activity) or FGF21 [73,82-86]. FGF21, a regulator of glucose and lipid homeostasis, is a substrate 
of circulating FAP-α in the human plasma. FGF21 has three potential Pro residues for Pro-specific 
proteases. At the position 2 and 4 of the N-terminus cleavage by DPP IV maintained FGF21 
activity. At the Gly170-Pro171 position, ten amino acids off the C-terminus, cleavage by FAP-α, but 
not POP, resulted in the loss of FGF21 activity [86]. Collagens are also recognized biological 
substrates of FAP-α. FAP-α degrades also gelatin, heat-denatured but not native collagen type I and 
IV, vitronectin, tenascin, laminin, fibronectin, fibrin or casein [87-91].  
Other biological peptides can also be hypothesized to be substrates of the prolyl endopeptidase 
activity associated with FAP-α. Thymosin β4, a widely distributed 43-amino acid peptide critical in 
tissue repair and remodeling and fibroblast differentiation is overexpressed in cancer and fibrosis. 
The profibrotic protein thymosin β4 N-terminus contains a four-amino acid sequence, Ac-Ser-Asp-
Lys-Pro- (Ac-SDKP-), which was shown to be released from thymosin β4 by prolylendopeptidases 
[92]. Thymosin β4 and its degradation product Ac-SDKP are able to reduce inflammation and 
fibrosis [93-96]. Matrikines, peptide fragments derived from the ECM, are neutrophil 
chemoattractants and regulators of endothelial permeability, and thus may also be of relevance in 
tissue repair. The sequential action of the MMP-8, MMP-9 and prolyl endopeptidases is critical in 
the generation from collagen of the tripeptide Pro-Gly-Pro (PGP) and acetylated-PGP matrikines, 
[97,98]. Roflumilast, an anti-inflammatory agent inhibiting phosphodiesterase-4, was shown to 
reduce pulmonary inflammation by decreasing prolyl endopeptidase activity and the generation of 
Ac-PGP and PGP [99]. 
FAP-α activity has also been used to activate functionalized chemotherapeutic prodrugs for other 
targets [100]. FAP-α activity was imaged in tissues in vivo by a Lys-Gly-Pro-Gly-Pro-Asn-Gln-
Cys-prodrug of a near infrared fluorescent probe [101]. CAFs were specifically targeted for 
photodynamic therapy using a photosensitizer coupled to the peptide TSGPNQEQK representing 
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the cleavage site of FAP-α on α2-antiplasmin [102]. The enzymatic activity of FAP-α was used to 
more selectively target a Thr-Ser-Pro-Arg-Ser-prodrug of the proteasome inhibitor bortezomib 
[103]. A Z-Gly-Pro-doxorubicin prodrug was shown to target FAP-α-expressing cells and to 
selectively release doxorubicin, being less cardiotoxic than free doxorubicin [104]. Nanomicelles 
loaded with the FAP-α substrate Z-Gly-Pro-doxorubicin prodrug were developed for selective 
delivery of doxorubicin to tumors [105]. The cytotoxins thapsigargin and melittin were also 
modified as FAP-α-activated prodrugs [106,107]. We have previously shown that double harmonic 
nanoparticles whose surface was functionalized with a covalent inhibitor of prolyl endopeptidases 
could specifically label cells expressing this activity [108].  
 
3.3. FAP-α inhibitors and antagonist: preclinical and clinical trials targeting FAP-α in cancer 
and fibrotic diseases. 
FAP-α in cancer. Tumors are heterogeneous populations of cells, which include the tumor cells, 
inflammatory and immune cells, endothelial cells and pericytes and cancer-associated 
(myo)fibroblasts (CAFs) expressing α-SMA and FAP-α, as a membrane-associated proteolytically 
active and easily accessible form. FAP-α is expressed in particular in the stroma directly 
surrounding epithelial cancers (Figure 4), but also in melanoma and sarcoma, in healing wounds as 
well as in chronic inflammation and fibrotic conditions [7,50,54,109-1178] but not in normal tissues 
or benign or premalignant tumors.  
 
Figure 4. FAP-α protein expression determined by immunohistochemistry (brown precipitate) in 
human normal colon tissue (left) and cancer (right). Both samples have been processed and 
evaluated according to standard diagnostic procedures and are from the same patient. 
 
Depending on the particular cancers and conditions, FAP-α can act as a tumor promoter or 
suppressor, dependent or independent of its enzymatic activity [72,77,113]. For example, FAP-α 
expression in stromal cells of breast and lung cancers may also be possibly associated with longer 
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survival [110,117]. FAP-α has been involved in cancer progression by interfering with the functions 
of the cancer microenvironment, the cancer stroma [74,83,113,114,119-122]. The proteolytic 
activity of FAP-α is pro-fibrogenic but the protein itself is a regulator of cell apoptosis, adhesion 
and migration, independently of its enzymatic activity [68,83,121,122,123]. FAP-α participates in 
malignant melanoma cell invasion of the ECM by interacting with β1-integrins in a collagen-
dependent manner [60,124-127] and promotes glioma cell invasion through the brain parenchyma 
by degrading the proteoglycan brevican [30,63]. FAP-α also interacts with other cell membrane 
proteins, including urokinase-type plasminogen activator receptor (uPAR) localizing this receptor to 
the invadopodia that are associated with degradation of the ECM in cancer invasiveness and 
metastasis [82,124,126,128,129]. Splice transcript variants of FAP-α encoding different isoforms 
have been found, some of them devoided of enzymatic activity and of cell surface expression 
[77,72]. A variant of FAP-α encoding a truncated isoform (239 amino acids, 27 kDa) missing part 
of the cytoplasmic, transmembrane and membrane proximal domains but overlapping the carboxy-
terminal catalytic region has been identified in human melanoma cells [53]. In carcinogenesis, FAP-
α expression is up-regulated during tumor stem cell differentiation by TGF-β, FGFR1, 12-O-
tetradecanoyl phorbol-13-acetate and retinoids [51]. However, interactions with the other members 
of the family must be considered. Both FAP-α and POP are overexpressed in cancer, regulating 
tissue remodeling, angiogenesis and immune tolerance. DPP IV and FAP-α have been inversely 
involved in the progression of carcinomas and melanomas. DPP IV is down-regulated during the 
neoplasic transformation of melanocytes, coincident with an increase in their invasive potential 
[131], growth factor independence [128,129], and interaction with endothelial cells [31,63,130-
134]. FAP-α and DPP IV are frequently co-expressed and can form heterodimers that enable 
fibroblasts to migrate [135,136]; so that in terms of invasiveness, both enzymes seem to cooperate. 
Preclinical studies have evaluated the therapeutic interest of FAP-α with some promising results: 
FAP-α-expressing cells suppressed antitumor immunity in an experimental model of pancreas 
cancer; in a transgenic mouse model of lung carcinomas, the ablation of FAP-α caused necrosis of 
both cancer and stromal cells; in other murine models of lung and colon carcinoma FAP-α 
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inhibition slowed the growth of the tumors; FAP-α expression was also shown to improve the 
uptake of chemotherapeutics in multiresistant cancers [137-139].  
Altogether, FAP-α inhibition is generally considered a potential therapeutic target for oncologic 
diseases. Three general approaches to inhibit/antagonize FAP-α have been used experimentally and 
in a very limited number of preclinical and clinical trials: (i) synthetic small molecule inhibitors of 
FAP-α activity, (ii) anti-FAP-α antibodies and immunotherapeutics and (iii) genetic deletion of the 
FAP-α protein. These combined approaches allowed the emerging recognition of the role of FAP-α 
protein in cancer progression. As CAFs expressing high levels of FAP-α can indirectly inhibit 
tumor growth by controlling the functions of the tumor stroma, several attempts have targeted this 
population of tumor-associated cells.  
Synthetic inhibitors of FAP-α. As stated previously, the active site and enzymatic mechanism of 
FAP-α are very similar to those of the other members of the DPP IV family of serine proteases, in 
particular DPP IV itself and POP. Most known FAP-α inhibitors often resemble the dipeptide 
cleavage products, with a boroproline at the P1 site; however, many of these inhibitors also inhibit 
DPP IV, DPP-II, DPP8 and/or DPP9. Thus, synthetic small molecule inhibitors developed for 
members of the family, in particular DPP IV and POP, may be considered as potential inhibitors of 
FAP-α exopeptidase and endopeptidase activities. The cross-inhibitory properties for FAP-α of 
inhibitors developed for POP, DPP8/9 or DPP IV [21,32,61,69,99,140-157] was generally not 
evaluated in detail, with some exceptions (Table 3). Thus, the challenge has been in identifying 
inhibitors that are selective for FAP-α over both the dipeptidyl peptidases with which it shares 
exopeptidase specificity, and prolyl oligoendopeptidases, with which it shares e ndopeptidase 
specificity.  
The design of families of small organic synthetic inhibitors of FAP-α, either covalent or non-
covalent inhibitors, has been initially based on previously developed DPP IV and POP inhibitors. 
Then selectivity was further refined and the molecules evaluated in experimental and preclinical 
biomedical models. Many DPP IV inhibitors are known and several are marketed as drugs [21]. 
Whereas selectivity toward the strict exopeptidase DPP IV, which requires a free N-terminal amino 
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acid, has been achieved, selectivity toward the other prolyl-specific endoproteases gelatinases of the 
family, in particular POP, is much more difficult to obtain (Figure 5). Thus, the issue of POP 
selectivity is not always achieved and unfortunately not always evaluated in published results.  
 
Figure 5. FAP-α and POP amino acid sequence specificities and consequences for developing 
specific inhibitors.  
 
The lead molecule in the development of POP inhibitors was Z-Pro-prolinal. The structural 
characteristics of the inhibitor-POP complex were determined [151]. In POP the presence of 
hydrophobic residues, such as Cys255 and Trp595, forms a non-polar environment for the indole ring 
of inhibitors [88], providing a window to develop selective inhibitors able to discriminate between 
the two enzymes. Whereas POP inhibitors selective toward FAP-α, have been prepared using 
molecular modeling [32,148], very few inhibitors with selectivity for FAP-α versus POP have been 
developed [61,62,143,147,149,150,152,153]. 
 
Table 3. Synthetic inhibitors of FAP-α. 
 
Boronic acid derivatives are reversible covalent inhibitors of serine proteases, therefore most, but 
not all, FAP-α inhibitors contain a boronic acid group. The most studied small molecule inhibitor is 
the dual DPP IV/FAP-α inhibitor PT-100/talabostat (5). PT-100 (5) inhibits 90% of DPP IV-like 
exopeptidase activity, but only 20% of the FAP-α endopeptidase activity forming a high affinity 
complex between the active site Ser and the boron [154,155]. PT-100 (5) was safe in patients and 
upregulated cytokine expression, an effect that was mediated by the inhibition of FAP-α, not by 
DPP IV [156]. PT-100 (5) was not directly cytotoxic in vitro but caused regression of tumors in 
vivo involving tumor-specific cytotoxic T lymphocytes (CTLs), and production of cytokines and 
chemokines promoting T-cell effector functions [157]. In some preclinical models, PT-100 (5) 
decreased the growth of tumors [138,157], but not in all models [112,113]. Combining the dual 
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DPP IV/FAP-α inhibitor PT-100 (5) with oxaliplatin enhanced the efficacy of chemotherapy by 
modifying the tumor microenvironment [158]. The administration of PT-100 (5) demonstrated 
clinical response in a phase II trial of stage IV melanoma patients [159-161], but further research is 
presently suspended. A PT-100 (5) analog, PT-630 (6), a dual FAP-α/DPP IV inhibitor that does not 
permeate cell membrane, was shown to decrease experimental lung and colon tumor growth. FAP-α 
enzymatic activity was inhibited, but not FAP-α protein expression in the tumor extracts [117]. 
Starting from a FAP-α/POP non-specific lead, rounds of refinements produced a FAP-α-specific, 
ARI-3009 (1) inhibitor [149], but presently no pre-clinical or clinical data have been reported. The 
binding of the cyclic amide boronic acid-based inhibitor (2) developed by Tran and co-workers [69] 
in the active sites of FAP-α, DPPIV and POP was explored by docking studies. Interaction with 
specific amino acids in the three enzymes was demonstrated, blockade of the N-terminus of the 
inhibitors providing selectivity for FAP-α and POP versus DPP IV. The phenyl ring of the inhibitor 
is located partially outside of the active pocket and was not directly involved in the binding. We 
took advantage of this observation to achieve chemical modification using copper-free click 
chemistry of this phenyl ring to prepare nanoparticles presenting a prolyl endopeptidase inhibitor at 
their surface to label human cells [107]. To identify peptide motifs for designing FAP-α-selective 
inhibitors, dipeptide substrate libraries of the chemical structures P2-Pro1 and acetyl (Ac)-P2-Pro1 
were used, where P2 was varied [61,62]. The results designed Ac-Gly-boroPro (3) as FAP-α lead 
inhibitor design, selective versus DPP IV, DPP-7, DPP-8, DPP-9 and POP. The pseudopeptide 
acetyl-Arg-2-(2-(2-aminoethoxy)ethoxy)acetic acid-(D)Ala-(L)boroPro (13), a dual FAP-α/POP 
inhibitor, reduced tumor growth more than a monospecific POP inhibitor [108]. Optimization of a 
nonselective DPP IV inhibitor led to the discovery of a class of substituted 4-
carboxymethylpyroglutamic acid diamides (4) as carbonitrile-based FAP-α inhibitors, selective 
versus DPP-IV, DPP-II, DPP8, and DPP9 [145]. Unfortunately, selectivity toward POP was not 
reported. A series of carbonitrile inhibitors, N-acetylated-Gly-(2-cyano)pyrrolidines (14,15), where 
the acyl and lipophilic cyanopyrrolidine substituents were systematically varied, provided 
compounds with selectivity for FAP-α versus the other members of the family but no biological 
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evaluation was reported [143]. Starting from the FDA-approved xanthine-based DPP IV inhibitor 
linagliptin [21], which also displays significant FAP-α potency, substitutions on N1, N7 and C8 of 
the xanthine scaffold were investigated, allowing the identification of the first selective xanthine-
based FAP-α inhibitors (7) with low micromolar potency [152]. A series of FAP-α inhibitors based 
on a N-4-quinolinoyl-Gly-(2S)-cyanoPro (8) scaffold has demonstrated low nanomolar FAP-α 
inhibition combined with high selectivity with respect to both the dipeptidyl peptidases and POP. 
Pharmacokinetic evaluation of selected inhibitors in rats demonstrated high oral bioavailability, 
plasma half-life and the potential to selective complete FAP-α inhibition in vivo [150,153]. From a 
series of diphenylphosphonates, modest selectivity for FAP-α versus DPP IV could be achieved 
with the Gly-ProP(OPh)2 derivative (9), but anti-invasive properties were demonstrated only in vitro 
[147].  
 
Antibody-based antagonists and immunotherapeutics. Anti-FAP-α antibodies were shown to very 
selectively target tumors [162] and were safe [115]. In a preclinical murine xenograft model of 
human HT-29 colon cancer cells, treatment with anti-FAP-α antisera inhibiting dipeptidyl peptidase 
activity attenuated tumor growth [163]. The humanized monoclonal anti-FAP-α antibody 
F19/sibrotuzumab requires the tertiary structure of the protein for binding but does not inhibit FAP-
α activity and is not directly cytotoxic. Several phases I and a limited phase II clinical trials have 
been conducted using F19/sibrotuzumab. The treatment was well tolerated in patients with 
advanced FAP-α-expressing cancers as it specifically accumulated in tumors and not in normal 
tissues, but no clinical response was observed [115,162,164]. The expression of the cell surface 
FAP-α was depleted in CAFs with an anti-FAP-α internalizing antibody, suppressing the invasive 
and pro-tumorigenic properties of these cells [165], showing that the expression of the protein at the 
cell surface is necessary for cancer progression and that FAP-α eradication is necessary for blocking 
the pro-tumorigenic role of CAFs. Anti-FAP-α antibodies conjugated to cytotoxic/cytostatic 
chemotherapeutics have been also evaluated in clinical trials [117]. The tubulin inhibitor 
mertansine/DM1/FAP-α-antibody-drug conjugate inhibited tumor growth and induced tumor 
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regression in a preclinical model [166]. An immunotoxin combining an anti-FAP-α antibody with 
the Pseudomonas exotoxin 38 (PE38), which prevents protein synthesis in cells was developed to 
specifically deplete CAFs.  In experimental breast cancer or established experimental melanoma, 
treatment decreased tumor burden, likely mediated by modulation of the immune tumor 
microenvironment. [167,168] The indoleamine-2,3-dioxygenase (IDO, a potent immunoregulatory 
mediator) inhibitor, 1-methyl-tryptophane was conjugated to a FAP-α fragment (aa245-467) to 
produce a tumor vaccine and boost the anti-tumor immune response by IDO inhibition following 
dissociation from the FAP-α fragment [169]. Targeting tumor infiltrating T cells with a bispecific 
mGITRL-FAP-α-fusion protein could induce tumor rejection while minimizing systemic 
autoimmune side effects [170]. Targeting tumor stroma with chimeric antigen receptor engineered 
T-cells (CAR-T cells) expressing FAP-α was also successfully developed for cancer 
immunotherapy with some efficacy, however, they induced significant cachexia and lethal bone 
toxicities in murine tumor models [171-173]. 
 
Genetic deletion of the protein. The expression of FAP-α was depleted from CAFs surface using 
siRNA or shRNA technologies [115,117,165,174]. FAP-α knockdown reduced FAP-α expression, 
inhibited tumor growth, promoted collagen accumulation and suppressed angiogenesis and the 
invasive properties of these cells, showing that the expression of the protein at the cell surface is 
necessary for cancer progression and that FAP-α eradication is mandatory for blocking the pro-
tumorigenic role of CAFs. 
 
Inhibition/antagonism of FAP-α in fibrogenic and inflammatory diseases. Fibrosis is the final 
pathway of many progressive chronic diseases [2]. Presently, only very few drugs have been 
clinically approved as antifibrotic therapeutics. The evaluation of the inhibition/antagonism of FAP-
α has been much less studied in fibrogenic and inflammatory diseases than in oncologic diseases. 
The mediators of fibrosis include inflammatory mediators, cytokines and chemokines, reactive 
oxygen/nitrogen species, several proteases, the endothelin and angiotensin systems and growth 
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factors, in particular TGFβ and PDGFs and their cognate receptors, associated to the accumulation 
of ECM proteins, in particular type I and type III collagens, produced by myofibroblasts. This 
ultimately destroys the structure of an organ leading to loss of function. Renal fibrosis 
(glomerulosclerosis and interstitial fibrosis with tubular atrophy) is the final consequence of all 
chronic kidney diseases and a result of immune and non-immune injuries after kidney 
transplantation leading to chronic allograft dysfunction [1]. Diabetic nephropathy is associated with 
increased expression of DPP IV on endothelial and tubular epithelial cells. The dual DPP IV/ FAP-
α inhibitor linagliptin has incretin-independent anti-fibrotic effects in diabetic nephropathy by 
inhibiting interaction of DPP IV with the integrin β1 [94]. FAP-α was shown to be specifically 
overexpressed by profibrogenic stimuli in myofibroblasts of intestinal strictures in Crohn’s disease 
[175]. Iterestingly, in the fibrotic lung FAP-α increased collagen catabolism and clearance in 
concert with MMPs, showing protective effects [90]. 
 
4. Conclusion 
The cell surface serine protease FAP-α participates in ECM degradation and is involved in many 
cellular processes, including tissue remodeling, fibrosis, wound healing, inflammation and tumor 
progression. FAP-α exhibits post-proline cleaving exopeptidase and gelatinase/collagenase 
endopeptidase activities and some biological substrates of FAP-α have been determined. Both 
active and enzymatically inactive FAP-α proteins have biological functions. FAP-α has been 
involved in many stages of oncogenesis, from initiation to progression and metastasis and the strong 
correlation between CAFs and FAP-α expression suggest that it is a relevant target for cancer 
diagnosis and treatment. Studies aiming at blocking FAP-α functions in cancer have included 
targeting FAP-α-expressing cells by inhibiting FAP-α enzymatic activity, developing anti-cancer 
vaccines and genetic deletion of FAP-α. The information obtained indicated that FAP-α expression 
in cancer-associated stromal cells was likely a more relevant candidate for therapeutic intervention 
than in the cancer cells themselves. The effects of inhibitors of FAP-α activity or deletion/ablation 
of the protein in experimental cancer models suggested that the enzymatic activity and the presence 
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of the protein in the cancer stroma were critical for FAP-α tumor growth promoting activity. The 
initial clinical trials using either anti-FAP-α antibodies or not very selective synthetic inhibitors 
were up to now disappointing, but showed that interfering with FAP-α does not induce side-effects.  
 
5. Expert opinion  
FAP-α expression is associated with cancer, wound healing, tissue remodeling and chronic 
inflammation. Activated subpopulations of (myo)fibroblasts and  CAFs specifically express FAP-α, 
according to poorly understood mechanisms and during very defined stages of fibrogenic processes 
in the progression of the pathologies, suggesting a complex level of regulation. The mechanisms 
regulating FAP-α expression are not yet understood and will need to be defined. Thus, it will be 
necessary to better understand the basic biology of FAP-α not only in pathological situations like 
cancer and inflammation but also in normal situations such as tissue remodelling in healing to better 
define the therapeutic options in targeting this protein. It will also be necessary to identify the 
relevant biological substrates of FAP-α and to understand the mechanisms inducing/repressing 
FAP-α expression. The expression of FAP-α may be beneficial in some situations, like wound 
healing or some cancers, but it is generally detrimental in most cancers. FAP-α displays dual prolyl-
specific exopeptidase and endopeptidase activities, as well as non-enzymatic functions likely 
dependent on its association with other cellular proteins. Therefore, for therapeutic purposes it will 
be of utmost importance to study the best options, either inhibiting the two peptidase activities or 
only one of them, or abrogating the expression of the protein. A few synthetic inhibitors able to 
discriminate between FAP-α activity and the other members of the family have now been designed. 
In the few clinical trials for cancer performed up to now, antagonizing FAP-α seemed to induce 
positive outcome, but the selectivity of the synthetic inhibitors versus the other members of the 
family is an unresolved issue since it appears that the different proteins of the family may have 
opposing pathological functions. Thus, preclinical and clinical trials may now be undertaken to 
evaluate the effect of FAP-α selectivity, either as monotherapy or combined therapies which need to 
be defined. FAP-α has been shown to directly interact with other cellular proteins, such protein-
21 
 
protein interactions may offer new therapeutic opportunities to prevent the accumulation of 
proliferating fibroblasts and myofibroblasts and the development of disease-associated fibrosis. To 
date, few investigations on the effects of FAP-α inhibitors on fibroblast functions have been 
conducted and it is presently not known whether inhibition induces physiological changes on the 
long term in fibroblast functions. Finally, we believe that using FAP-α-specific prodrugs for 
delivering cytotoxic agents to FAP-α-expressing cells and tissues might be of greater therapeutic 
value in the future than the inhibition of the protease activity itself.  
 
Article highlight box  
- fibroblast activation protein-α (FAP-α) belongs to the prolyl-specific family of serine proteases, 
- FAP-α displays exopeptidase and endopeptidase activities shared by the same active site triad, 
- FAP-α is specifically expressed by cells and tissues under stress, but not during homeostasis, 
- FAP-α is a therapeutic target for stress-associated fibrogenic disorders, 
- for therapeutic purposes both inhibiting FAP-α activity and abrogating FAP-α protein expression 
seem to be necessary, 
- the design and therapeutic evaluation of inhibitors specific for FAP-α versus the other members of 
the family is mandatory before its true therapeutic value as a target can be ascertained. 
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Tables. 
Table 1. Mutagenesis experiments performed on FAP-α. 
 
aa mutated to   consequence             references 
________________________________________________________________________________
R
123
    A, M, E dipeptidyl and endopeptidase activities reduced   67  
________________________________________________________________________________ 
E
203
  A, D or Q dipeptidyl and endopeptidase activities reduced   67,68  
E
204
  A, D or Q when associated,        
   no inhibition of cell adhesion, migration and invasion 
________________________________________________________________________________ 
S
624
       A  dipeptidyl and gelatinase activities reduced       16,68  
   no inhibition of cell adhesion, migration and invasion 
S
656
       A  dipeptidyl and gelatinase activities reduced    67  
   no inhibition of cell adhesion, migration and invasion 
_______________________________________________________________________________ 
N
704
       A  dipeptidyl and endopeptidase activities reduced   67  
_______________________________________________________________________________ 
A
657
   F or V dipeptidyl and gelatinase activities reduced 
   D or N endopeptidase activity inhibited, dipeptidase activity increased 
 Q, S or T endopeptidase activity inhibited, dipeptidase activityunchanged  67  
________________________________________________________________________________ 
 
2 
 
 
Table 2. Kinetics parameters of FAP-α on small peptides. 
 
peptide sequence     KM          references 
_______________________________________________________________________________ 
exopeptidase activity 
Gly-Pro-      0.25 mM           16,61  
Ala-Pro-      0.24-0.46 mM   67  
Lys-Pro-      0,90 mM   16  
Ile-Pro-      0.10 mM   61  
Phe-Pro      0.24 mM   61  
 
endopeptidase activity 
Ac-Gly-Pro       0.33 mM    61  
Thr-Ser-Gly-Pro-Asn-Gln     1.3 µM    67  
Ala-Ser-Gly-Pro-Asn-Gln,    2.2 µM    62 
Thr-Ala-Gly-Pro-Asn-Gln     0.7 µM    62  
Thr-Ser-Gly-Pro-Ser-Gln    1.9 µM    62  
Thr-Ser-Gly-Pro-Asn-Ser    2.2 µM   62  
Ala-Ser-Gly-Pro-Ser-Ser     4.3 µM    62 
Arg-Gly-Thr-Ser-Gly-Pro-Asn-Gln-Glu-Gln-Glu  29 µM    73  
      (antiplasmin-cleaved sequence)  
_____________________________________________________________________________ 
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Table 3. Synthetic inhibitors of FAP-α. 
 
name   structure        IC50/Ki /selectivity                   references 
 
1 ARI3009       selective vs POP                      149  
______________________________________________________________________________ 
2 cyclic amide     Ki FAP-α = 7.5 nM      69 
boronic acid      Ki POP = 2.8 nM 
       Ki DPP IV = 22’780 nM 
______________________________________________________________________________ 
3 N-acetyl-Gly-   Ki FAP-α 23 nM               61,62 
boroPro   Ki POP 211nM  
    Ki DPP IV 377 nM    
_____________________________________________________________________________ 
4 4-carboxy-    IC50 FAP-α 20 nM                   145  
methyl-        IC50 DPP IV > 50 µM 
pyroglutamic   selective vs DPP-II, DPP8,  
acid diamide and DPP9  
______________________________________________________________________________ 
5 PT-100   Ki FAP-α 6.2 nM                            154,155  
Val-boroPro  Ki DPP IV 22 nM 
talabostat  Ki POP 980 nM 
______________________________________________________________________________ 
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6 PT-630                         Ki FAP-α 5 nM; IC50 FAP-α 23 nM     118  
Glu-boroPro-                Ki DPP IV 3 nM; IC50 DPP IV 3 nM 
thioxamide        
______________________________________________________________________________ 
7 xanthine-based   selective vs DPP IV           152  
linagliptin-derived 
_____________________________________________________________________________ 
8 N-4-quinolinoyl-                IC50 FAP-α 1.8 nM                150,153  
Gly-(2S)-cyanoPro             selective (>100)    
                            vs DPP IV and POP 
______________________________________________________________________________ 
9 Gly-Pro
P
(OPh)2  Ki DPP IV 59.4 nM                     147  
 Ki FAP-α   3.27 µM R=Gly  
                                               
 
10 Tyr-Pro
P
(OPh)2            Ki DPP IV 14.2 µM  
R=Tyr                        Ki FAP-α   2.59 µM 
11 Pro-Pro
P
(OPh)2             Ki DPP IV 42.8 µM   
R=Pro              Ki FAP-α   4.60 µM 
12 Val-Pro
P
(OPh)2            Ki DPP IV 3.13 µM 
R=Val              Ki FAP-α   3.63 µM 
______________________________________________________________________________ 
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13 N-acetyl-Arg-2-(2-          dual FAP-α/POP inhibitor   109 
(2-aminoethoxy)ethoxy)          Ki FAP-α  5.7 nM 
acetic acid-(D)Ala-           Ki POP  7.3 nM 
(L)boroPro (M83)  
    
______________________________________________________________________________ 
 
14 N-benzoyl-Gly-  selective vs DPP IV,DPPII,DPP9  143 
(2-cyano)pyrrolidine             IC50 FAP-α 0.85 µM     
   IC50 POP > 10 µM 
  
15 N-naphthoyl-Gly-   IC50 FAP-α 6.7 µM 
(2-cyano)pyrrolidine  IC50 POP > 100 µM 
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Legends for Figures 
Figure 1: Myofibroblast formation.  
Activated proliferating myofibroblasts develop from resting precursors, either resident tissue 
fibroblasts, or circulating fibrocytes, or following cell (epithelial or endothelial) transdifferentiation, 
perturbating tissue homeostasis. This process is mediated by the secretion of cell-derived activating 
factors, including cytokines, proteases, extracellular matrix proteins, and in particular TGFβ. The 
expression of specific molecules and the secretion of proteases by myofibroblasts drives the 
development of fibrogenic processes and indirectly influences a multitude of other cell types.  
 
Figure 2. Prolyl-specific peptidases: exoproteolytic (left) and endoproteolytic (right) enzymatic 
activities, with the preferred amino acid sequences when known.  
 
Figure 3. Structure of the FAP-α protein. 
A. Schematic structure of the amino acid sequence of FAP-α. Yellow: cytoplasic motif; green: 
transmembrane domain; pink: α/β hydrolase domains; grey: β-propeller domain; red arrows: 
catalytic Ser/Asp/His charge relay triad; blue arrows: substrate binding motif.;  
B. Overall 3D structure of the FAP-α dimer. Active site residues Ser624, Asp702 and His734 are 
located at the interface of the two monomers in the α/β-hydrolase domain of each monomer and the 
β-propeller domain; [PDB 1z68].  
 
Figure 4. FAP-α protein expression (brown precipitate) in human normal colon tissue (left) and 
cancer (right) determined by immunohistochemistry. 
 
Figure 5. FAP-α and POP aminoacid sequences specificities and consequences for developing 
specific inhibitors, left, exopeptidase activity, and right, endopeptidase activity (adapted from 
[61,62]).  
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